Correct administration and dose adjustment guide for Lynparib/Olaparib

Olaparib is a poly(ADP-ribose) polymerase (PARP) inhibitor that is widely used to treat patients with ovarian, breast, pancreatic and prostate cancer who carry BRCA1/2 mutations. Proper administration is crucial to ensure efficacy and reduce adverse reactions.

The recommended dose of olaparib is usually 300 mg (two 150 mg tablets each time), twice daily, for a total dose of 600 mg. However, specific dosages may vary depending on individual circumstances, tolerance, and treatment regimen. For patients with severe renal impairment, it is recommended to adjust the dose to 200 mg twice daily to reduce drug accumulation in the body. In addition, if the patient develops grade 3 or 4 toxic reactions during treatment, such as severe anemia, neutropenia, or thrombocytopenia, the doctor may temporarily stop the drug or reduce the dose, such as to 250 mg or 200 mg twice daily, until the patient can tolerate the treatment.

Patients should swallow olaparib capsules or tablets whole and avoid crushing, chewing or opening the capsules to ensure sustained release of the drug. If a dose is missed, the patient should take it as soon as possible on the same day, but not if it is close to the next dose to avoid overdose. In addition, olaparib may interact with certain drugs, such asCYP3A inhibitors (such as ketoconazole, clarithromycin) or CYP3A inducers (such as rifampicin, phenytoin). Therefore, these drugs should be avoided during medication to avoid affecting efficacy or increasing toxicity.

While taking Lynparza, patients need to regularly monitor blood routine, liver and kidney function, and bone marrow suppression, and adjust the dosage under the guidance of a doctor. If serious adverse reactions or tolerance issues occur, you should communicate with your doctor in time to optimize the treatment plan and ensure safety.

Reference materials:https://www.lynparza.com/